RESUMEN
@#AIM: To analyze the efficacy and safety of triamcinolone acetonide(TA)combined with macular grid photocoagulation in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO).<p>METHODS: A total of 147 patients(147 eyes)with ME secondary to BRVO treated in the hospital were enrolled between January 2016 and January 2020. They were randomly divided into observation group(73 eyes)and control group(74 eyes). The observation group was given intravitreal injection of TA and macular grid photocoagulation, while control group was given intravitreal injection of conbercept and macular grid photocoagulation. All were followed up for 6mo. Efficacy and safety indexes between the two groups were compared.<p>RESULTS:After treatment, best corrected visual acuity(BCVA, LogMAR)in both groups was improved. At 1mo after treatment, BCVA in observation group was better than that in control group(0.22±0.15 <i>vs </i>0.27±0.13, <i>P</i><0.05). At 6mo after treatment, BCVA of patients under 50 years in observation group was significantly better than that of patients under 50 years in control group(0.09±0.04 <i>vs </i> 0.14±0.06, <i>P</i><0.05).BCVA was the best in patients with type serous retinal detachment(SRD), followed by type ME and mixed type(<i>P</i><0.05). However, there was no significant difference in BCVA between any two groups in ME classifications(<i>P</i>>0.05). After treatment, central macular thickness(CMT)in both groups was significantly decreased. At 3mo after treatment, CMT in observation group was higher than that in control group(309.76±84.24μm <i>vs </i>258.75±88.76μm, <i>P</i><0.01). At 1wk, 1, 3 and 6mo after treatment, intraocular pressure in observation group was higher than that in control group(<i>P</i><0.01). At 6mo after treatment, blood flow density of superficial capillary plexus(SCP)in both groups was significantly higher than that before treatment(<i>P</i><0.05), but there was no significant change in blood flow density of deep capillary plexus(DCP)or the area of foveal avascular zone(FAZ)(<i>P</i>>0.05). The incidence of increased intraocular pressure was higher in observation group than control group(28.8% <i>vs </i>14.9%), and times of intravitreal injection were fewer than those in control group(1.21±0.74 times <i>vs </i>3.62±2.08 times).<p>CONCLUSION: TA combined with macular grid photocoagulation in the treatment of ME secondary to BRVO can maintain visual acuity at a certain level in the short term. The curative effect is comparable to that of conbercept combined with macular grid photocoagulation in terms of improving visual acuity and CMT. However, there is increased intraocular pressure, and the intraocular pressure monitoring needs to be strengthened.
RESUMEN
@#AIM: To evaluate the efficacy of intravitreal injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema. <p>METHODS: In this prospective cohort study, total 78 patients(101 eyes)diagnosed with diabetic macular edema in Dongguan People's Hospital from October 2016 to December 2018 were randomly divided into two groups. 40 patients(52 eyes)were in combination therapy group and 38 patients(49 eyes)were in monotherapy group. The changes of best corrected visual acuity(BCVA), central retinal thickness(CRT)and frequency of injections in two groups were compared after 12mo follow-up.<p>RESULTS: At the end of 12mo follow up, the BCVA(0.44±0.22 <i>vs</i> 0.55±0.23)and CRT(335.3±65.9μm <i>vs</i> 370.4±84.4μm; <i>P</i><0.05)were better in combination therapy group than that in monotherapy group. Fewer injections were required in combination therapy group compared with that in the monotherapy group(4.04±1.08 <i>vs</i> 5.83±1.92 injections, <i>t</i>= -5.722, <i>P</i><0.05). There was no significant difference between two groups(13.87±2.55 <i>vs</i> 14.04±2.69mmHg, <i>P</i>>0.05)in intraocular pressure. <p>CONCLUSION: Combination therapy of ranibizumab and macular grid photocoagulation was an effective treatment for DME patients, could significantly reduced the frequency of injections, and represent a superior therapeutic approach to DME patients.
RESUMEN
Objective To investigate the effects of intravitreal injection of conbercept on diffuse macular edema (DME) of diabetes mellitus.Methods Together 51 diabetic patients (51 eyes) with diffuse macular edema were collected between July 2016 to July 2017,and randomly divided into three groups (n =17):group A,in which patients received solely intravitreal injection of 0.5 mg conbercept,group B,those who was intravitreally injected with 0.5 mg of conbercept and modified macular grating photocoagulation,and group C,patients undergoing modified grid photocoagulation (GPG).Then,before treatment and 1 week,1 month,3 months and 6 months after treatment,all patients were examined by optical coherence tomography for determining central macular thickness (CMT),followed by fundus fluorescein angiography (FFA),the best corrected visual acuity (BCVA),slit lamp,intraocular pressure for compare the efficacy and safety of the three procedures.Results All the three treatments improved BCVA,CMT,retinal neovascularization (RNV) leakage in diffuse DME patients,but group A and B were better than group C (both P ＜ 0.05),while there was no significant difference in BCVA improvement between A and B group (P ＞ 0.05),whereas the improvement in CMT of group B patients was better than that of group A [(197.47 ±45.26) μm vs.(205.59 ± 47.33) μm] (P ＜ 0.001),and this was true of RNV leakage [(9.91 ±3.18)mm vs.(13.24 ±4.87) rnm] (P＜0.001),without related complications.Conclusion Combination of modified macular grid photocoagulation and intravitreal injection of conbercept can quickly relieve diabetic macular edema and alleviate neovascularization,thus improving the patients' vision acuity,of which the efficacy is superior to the pure modified macular grid photocoagulation and conbercept injection.